Amenamevir

Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).

Amenamevir
Clinical data
Trade namesAmenalief
Other namesASP-2151, ASP2151
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC24H26N4O5S
Molar mass482.56 g·mol−1
3D model (JSmol)

It acts as an inhibitor of helicase-primase.[1][2]

Amenamevir was approved in Japan for the treatment of shingles in 2017.[3]

References

  1. Kawashima, Makoto; Nemoto, Osamu; Honda, Mariko; Watanabe, Daisuke; Nakayama, Juichiro; Imafuku, Shinichi; Kato, Toshiyuki; Katsuramaki, Tsuneo (2017). "Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study". The Journal of Dermatology. 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394.
  2. Yajima, Misako; Yamada, Hiroshi; Takemoto, Masaya; Daikoku, Tohru; Yoshida, Yoshihiro; Long, Tan; Okuda, Tomoko; Shiraki, Kimiyasu (2017). "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor". Antiviral Research. 139: 95–101. doi:10.1016/j.antiviral.2016.12.008. PMID 28027917.
  3. "Maruho Receives Manufacturing and Marketing Approval for Anti-Herpes Virus Agent "Amenalief® Tab. 200mg" in Japan" (Press release). evaluategroup.com. July 3, 2017.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.